Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NLS Pharmaceutics AG (NLSPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/25/2025: NLSPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1687887 |
Shares Outstanding - | Shares Floating 1687887 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, formerly known as NLS Pharma AG, was founded in 2012. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of neurological and psychiatric disorders. A significant milestone was its merger with Ascendia Pharmaceuticals in 2022, which aimed to strengthen its drug development capabilities. The company has undergone a strategic shift to focus on its lead drug candidate, quilienceu00ae. The company has a history of navigating early-stage clinical development and seeking strategic partnerships.
Core Business Areas
- Pharmaceutical Development: NLS Pharmaceutics AG's core business is the research, development, and eventual commercialization of pharmaceutical products targeting underserved medical needs in neurology and psychiatry. The primary focus is on its lead drug candidate, quilienceu00ae, for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Leadership and Structure
NLS Pharmaceutics AG is led by a management team with expertise in pharmaceutical development and business operations. The exact composition of the current leadership team and detailed organizational structure can be found on their investor relations website or in their SEC filings. As of recent public information, key roles typically include a CEO, Chief Medical Officer, and Chief Financial Officer.
Top Products and Market Share
Key Offerings
- Description: quilienceu00ae is NLS Pharmaceutics' lead drug candidate, a novel, low-dose, extended-release formulation of clozapine designed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and potentially children. Its unique formulation aims to reduce side effects associated with traditional clozapine. Currently, it is in late-stage clinical development. Market share data is not yet applicable as it is not yet commercially launched. Key competitors in the ADHD market include stimulant medications (e.g., Adderall, Ritalin) and non-stimulant medications (e.g., Strattera, Intuniv) from companies like Takeda, Novartis, and Shire (now part of Takeda).
- Product Name: quilienceu00ae (clozapine-<bos>-sorted nanomicelle formulation)
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the neurology and psychiatry sector, is characterized by high R&D costs, long development cycles, and stringent regulatory requirements. The ADHD market is substantial, driven by increasing diagnoses and a demand for effective and well-tolerated treatments. The market is competitive with established players offering various therapeutic options.
Positioning
NLS Pharmaceutics AG is positioning itself as an innovator in the treatment of ADHD with quilienceu00ae, aiming to offer a differentiated therapeutic profile that addresses unmet needs regarding efficacy and side effect management. Its positioning relies on the successful clinical validation and regulatory approval of quilienceu00ae to carve out a niche in a competitive landscape.
Total Addressable Market (TAM)
The global ADHD market is a multi-billion dollar market, with projections indicating continued growth. NLS Pharmaceutics AG is positioned to capture a segment of this TAM with quilienceu00ae, contingent on its successful development and market entry. The TAM is estimated to be tens of billions of dollars globally, with significant portions in North America and Europe.
Upturn SWOT Analysis
Strengths
- Novel drug formulation with potential for improved efficacy and safety profile.
- Focus on a significant unmet need in the ADHD market.
- Experienced management team in pharmaceutical development.
- Potential for intellectual property protection.
Weaknesses
- Relatively early stage of product development for quilienceu00ae.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
- Lack of a diversified product pipeline.
- Dependence on external funding.
Opportunities
- Growing demand for effective ADHD treatments.
- Potential for strategic partnerships or acquisition by larger pharmaceutical firms.
- Expansion into pediatric ADHD market after adult approval.
- Exploration of quilienceu00ae for other neurological or psychiatric indications.
Threats
- Clinical trial failures or unexpected adverse events.
- Regulatory hurdles and delays in approval processes.
- Intense competition from established ADHD treatments and new entrants.
- Patent challenges and generic competition upon patent expiry.
- Changes in healthcare reimbursement policies.
Competitors and Market Share
Key Competitors
- Takeda Pharmaceutical Company (TAK)
- Novartis AG (NVS)
- Pfizer Inc. (PFE)
- Johnson & Johnson (JNJ)
Competitive Landscape
NLS Pharmaceutics AG faces significant competition in the ADHD market from established pharmaceutical giants with broad portfolios and extensive marketing capabilities. Its advantage lies in the potential for a novel, differentiated treatment profile with quilienceu00ae. However, it faces disadvantages in terms of scale, resources, and market penetration compared to its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, NLS Pharmaceutics AG's growth trajectory has been tied to its pipeline progression, fundraising efforts, and strategic partnerships. Its evolution from a private entity to a publicly traded company (via SPAC merger) marks a significant step in its growth narrative. Financial growth, in terms of revenue, has been minimal due to its development stage.
Future Projections: Future projections for NLS Pharmaceutics AG are contingent on the successful clinical development and commercialization of quilienceu00ae. Analyst estimates, if available, would likely focus on potential peak sales of quilienceu00ae and the company's ability to achieve profitability post-launch. Successful regulatory approvals in major markets would be key drivers.
Recent Initiatives: Key recent initiatives include advancing quilienceu00ae through late-stage clinical trials, strengthening its management team, and focusing on the strategic direction of the company post-merger. These initiatives are aimed at de-risking the drug development process and preparing for potential commercial launch.
Summary
NLS Pharmaceutics AG is a biopharmaceutical company focused on developing quilienceu00ae for ADHD. Its strengths lie in its innovative drug candidate and potential market unmet needs. However, it faces significant weaknesses due to its early-stage development, reliance on clinical success, and limited resources. Opportunities for growth exist in the expanding ADHD market and potential partnerships, but threats from clinical failures, competition, and regulatory hurdles are substantial. Careful management of cash burn and successful clinical outcomes are critical for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Investor Relations Websites
- Financial News Outlets
- Pharmaceutical Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute investment advice. Financial data and market share figures are subject to change and may vary depending on the source. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.